drugset / Trial / NCT00239447

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447

Phase 3 Completed 131 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler

Timeline

Start
2002-11-26
Primary completion
2004-04-29
Completion
2004-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 5 ug Inhaled
Subject Tiotropium Other / unclassified 10 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled